<DOC>
	<DOCNO>NCT01604629</DOCNO>
	<brief_summary>The purpose study demonstrate patient Spondylarthropathies remission antiTNF therapy , maintain remission maintenance dose inferior currently recommend dose schedule .</brief_summary>
	<brief_title>Evaluation Protocol Dose Reduction Patients With Spondylarthropathies Clinical Remission With Anti-TNF</brief_title>
	<detailed_description>It show withdrawal treatment follow flare disease short time suspension evaluate controlled trial remission could maintain low dose . A multicenter , national , open-label , randomize control clinical trial 3 year duration ( 2 year inclusion + 1 year follow-up ) propose address issue . The study include 190 patient Spondylarthropathies stable treatment single anti-TNF agent compliance criterion clinical remission least 4 month . Patients randomized intervention control arm , stratification accord antiTNF product thet receive prior inclusion . Patients follow calendar visit recommend Spanish Society Rheumatology clinical practice . The propose hypothesis non-inferiority experimental arm dose reduction versus control arm standard treatment .</detailed_description>
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients older 18 year Patients Spondylarthropathies accord ASAS group criterion . Patients treatment antiTNF therapy ( infliximab , adalimumab , etanercept , golimumab ) present establish clinical remission Patients give inform consent participate study Patients secondary Spondylarthropathies Patients Spondylarthropathies predominantly clinical peripheral arthritis receive antiTNF therapy peripheral symp ton . Patients Spondylarthropathies associate disease hinders modify clinical evaluation patient ( fibromyalgia , chronic inflammatory disordersâ€¦ ) Patients bowel inflammatory disease Patients chronic therapy antiTNF therapy receive pattern reduction explore experimental group , low dos space experimental group study inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Spondylarthropathies</keyword>
	<keyword>Persistent clinical remission anti-TNF therapy</keyword>
	<keyword>Standardized protocol dose reduction anti-TNF therapy</keyword>
</DOC>